Arcellx To Share Two Presentations Including Updated Clinical Data From iMMagine-1, Phase 2 Pivotal Study Of Anitocabtagene Autoleucel In Patients With RRMM, At ASH 2025

-- A more recent data cut will be shared during an oral presentation for the iMMagine-1 study --

-- To date, no delayed neurotoxicities, including no Parkinsonism, no cranial nerve palsies, no Guillain-Barré syndrome, and no immune effector cell-associated enterocolitis have been observed with anito-cel --

-- FDA pre-BLA meeting for anito-cel has occurred; reiterating planned 2026 commercial launch --

-- Company to host a live webcast event with an expert panel of clinicians during ASH 2025 --

Arcellx, Inc. (NASDAQ:ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced it will share two presentations at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition taking place December 6-9, 2025, in Orlando, Florida, including updated clinical data from iMMagine-1, its Phase 2 pivotal study (publication #256) of anitocabtagene autoleucel (anito-cel) in patients with relapsed and/or refractory multiple myeloma (RRMM). Additionally, an abstract (publication #7644) describing the fast off-rate of anito-cel's D-Domain binder will be published in a supplemental issue of Blood in November 2025. The company will also have a medical affairs booth (#1363) at the Orange County Convention Center.